DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
» See Plans and Pricing
All Clinical Trials for Sulfur Hexafluoride Lipid-type A Microspheres
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03040323 | Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses | Recruiting | Indiana University | Phase 4 | 2016-12-22 | The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast. |
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | Not yet recruiting | National Cancer Institute (NCI) | N/A | 2017-10-09 | This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor. |
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | Not yet recruiting | University of Southern California | N/A | 2017-10-09 | This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor. |
| NCT03407001 | Lesion Detection in Cirrhotic Patients With Contrast Enhanced Ultrasound and the Accuracy of Contrast Enhanced Ultrasound Li-RADS for Hepatocellular Carcinoma (HCC) Diagnosis | Recruiting | National Cancer Institute (NCI) | Early Phase 1 | 2018-01-12 | The goal of this clinical research study is to find out if ultrasound scans using a contrast agent called Lumason (sulfur hexafluoride lipid-type A microspheres) can help doctors more easily find liver lesions (including hepatocellular carcinoma [HCC]), compared to ultrasounds without contrast agent. Contrast agents are drugs that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Researchers will also compare the effectiveness of liver ultrasounds using Lumason versus standard MRI imaging, in patients with cirrhosis of the liver. This is an investigational study. Ultrasound and MRI scans on this study are performed using FDA-approved and commercially available methods. Up to 150 patients will be enrolled on this research study. All will take part at MD Anderson. |
| NCT03407001 | Lesion Detection in Cirrhotic Patients With Contrast Enhanced Ultrasound and the Accuracy of Contrast Enhanced Ultrasound Li-RADS for Hepatocellular Carcinoma (HCC) Diagnosis | Recruiting | M.D. Anderson Cancer Center | Early Phase 1 | 2018-01-12 | The goal of this clinical research study is to find out if ultrasound scans using a contrast agent called Lumason (sulfur hexafluoride lipid-type A microspheres) can help doctors more easily find liver lesions (including hepatocellular carcinoma [HCC]), compared to ultrasounds without contrast agent. Contrast agents are drugs that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Researchers will also compare the effectiveness of liver ultrasounds using Lumason versus standard MRI imaging, in patients with cirrhosis of the liver. This is an investigational study. Ultrasound and MRI scans on this study are performed using FDA-approved and commercially available methods. Up to 150 patients will be enrolled on this research study. All will take part at MD Anderson. |
| NCT03652636 | Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions | Recruiting | Indiana University | Phase 4 | 2019-02-25 | In patients with hepatic lesions, to evaluate the efficacy of contrast enhanced ultrasound compared to MRI in differentiating focal nodular hyperplasia and hepatic adenoma. |
| NCT03687502 | The Role of Contrast Enhanced Ultrasound in Appendicitis | Recruiting | Children's Mercy Hospital Kansas City | Phase 2 | 2019-01-04 | This study seeks to determine the efficacy of Contrast Enhanced Ultrasound (CEUS) in improving the diagnosis of acute appendicitis in children, when compared to the standard grey-scale ultrasound. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Sulfur Hexafluoride Lipid-type A Microspheres
Condition Name
Clinical Trial Locations for Sulfur Hexafluoride Lipid-type A Microspheres
Trials by Country
Clinical Trial Progress for Sulfur Hexafluoride Lipid-type A Microspheres
Clinical Trial Phase
Clinical Trial Sponsors for Sulfur Hexafluoride Lipid-type A Microspheres
Sponsor Name
